Photo by bermixstudio from unsplash
Increased hepatic fat and cardiac fat are common in patients with type 2 diabetes mellitus (T2DM) and are associated with a greater risk of liver fibrosis and cardiovascular (CV) events.… Click to show full abstract
Increased hepatic fat and cardiac fat are common in patients with type 2 diabetes mellitus (T2DM) and are associated with a greater risk of liver fibrosis and cardiovascular (CV) events. Sex‐specific differences of dipeptidyl peptidase‐four (DPP‐4) inhibitor effects on hepatic (HCL) and myocardial fat content (MYCL) have not yet been evaluated.
Keywords:
reduces hepatic;
fat;
gliptin therapy;
hepatic myocardial;
therapy reduces;
myocardial fat
Journal Title: European Journal of Clinical Investigation
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Clinical Investigation
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!